Caissa Capital Management ltd.'s Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Jun 27, 2023
- Accession no.
- 0001929354-23-000016
- Filed
- Jun 27, 2023
- Trade date
- Jun 26, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $1.03M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Caissa Capital Management ltd.CIK 0001929354 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2023 | Common Stock | PPurchaseDisposed | −1,425,700 | $0.64F2 | −$912,448 | 0 | Indirect | |
| Jun 26, 2023 | Common Stock | PPurchaseDisposed | −182,300 | $0.62 | −$113,026 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.84, inclusive.
Referenced by the price of 1 transaction in Table I.